AstraZeneca “Obesity treatment drug, early clinical trial results show safety”

▲ AstraZeneca‘s experimental weight loss drug AZD5004 was found to be safe in early-stage clinical trials and showed similar side effects to the GLP-1 drug. (Photo = DB)

[메디컬투데이=최재백 기자] AstraZeneca’s weight loss drug AZD5004 was found to be safe in early-stage clinical trials and showed similar side effects to GLP-1 drugs.

AstraZeneca (AZN.L) said its experimental drug AZD5004, a pill for weight loss, was safe in early-stage clinical trials and showed similar side effects to the GLP-1 drug.

AstraZeneca conducted a phase 2 clinical trial following the phase 1 clinical trial that evaluated the safety and tolerability of AZD5004 in 72 healthy, non-obese volunteers or type 2 diabetes patients.

AstraZeneca reported that AZD5004, taken once a day, caused fewer side effects than injectable obesity treatments such as Eli Lilly’s Zebbound or Novo Nordisk’s Wegobi.

They stated that there were no serious side effects, and that the side effects of nausea and vomiting increased in a dose-dependent manner, but were at a similar level to GLP-1 receptor agonists such as Zebbound and WiGobee.

In particular, they argued that AZD5004 is superior to treatments from other competing pharmaceutical companies in that it can be mixed with other drug molecules, because more than 60% of obese and overweight patients are diagnosed with more than one disease.

Medical Today Reporter Jaebaek Choi (jaebaekchoi@mdtoday.co.kr)

[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]